JP2009523140A - 瘢痕形成または血管形成効果を有する医薬の製造のためのトリアジン誘導体の使用 - Google Patents

瘢痕形成または血管形成効果を有する医薬の製造のためのトリアジン誘導体の使用 Download PDF

Info

Publication number
JP2009523140A
JP2009523140A JP2008549781A JP2008549781A JP2009523140A JP 2009523140 A JP2009523140 A JP 2009523140A JP 2008549781 A JP2008549781 A JP 2008549781A JP 2008549781 A JP2008549781 A JP 2008549781A JP 2009523140 A JP2009523140 A JP 2009523140A
Authority
JP
Japan
Prior art keywords
alkoxy
alkyl
aryl
halogen
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008549781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009523140A5 (cg-RX-API-DMAC10.html
Inventor
ジェラール モワネ、
ダニエル クラヴォ、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2009523140A publication Critical patent/JP2009523140A/ja
Publication of JP2009523140A5 publication Critical patent/JP2009523140A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2008549781A 2006-01-13 2006-12-18 瘢痕形成または血管形成効果を有する医薬の製造のためのトリアジン誘導体の使用 Pending JP2009523140A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0600347A FR2896161B1 (fr) 2006-01-13 2006-01-13 Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
PCT/EP2006/012183 WO2007079915A2 (en) 2006-01-13 2006-12-18 Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect

Publications (2)

Publication Number Publication Date
JP2009523140A true JP2009523140A (ja) 2009-06-18
JP2009523140A5 JP2009523140A5 (cg-RX-API-DMAC10.html) 2010-02-12

Family

ID=36658622

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008549781A Pending JP2009523140A (ja) 2006-01-13 2006-12-18 瘢痕形成または血管形成効果を有する医薬の製造のためのトリアジン誘導体の使用

Country Status (22)

Country Link
US (1) US8217040B2 (cg-RX-API-DMAC10.html)
EP (1) EP1971329B1 (cg-RX-API-DMAC10.html)
JP (1) JP2009523140A (cg-RX-API-DMAC10.html)
KR (1) KR101482686B1 (cg-RX-API-DMAC10.html)
CN (1) CN101355931A (cg-RX-API-DMAC10.html)
AR (1) AR059034A1 (cg-RX-API-DMAC10.html)
AU (1) AU2006334732B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0620983B8 (cg-RX-API-DMAC10.html)
CA (1) CA2636838C (cg-RX-API-DMAC10.html)
CY (1) CY1119872T1 (cg-RX-API-DMAC10.html)
DK (1) DK1971329T3 (cg-RX-API-DMAC10.html)
EA (1) EA016127B1 (cg-RX-API-DMAC10.html)
ES (1) ES2647912T3 (cg-RX-API-DMAC10.html)
FR (1) FR2896161B1 (cg-RX-API-DMAC10.html)
HU (1) HUE037217T2 (cg-RX-API-DMAC10.html)
IL (1) IL192595A (cg-RX-API-DMAC10.html)
LT (1) LT1971329T (cg-RX-API-DMAC10.html)
PL (1) PL1971329T3 (cg-RX-API-DMAC10.html)
PT (1) PT1971329T (cg-RX-API-DMAC10.html)
SI (1) SI1971329T1 (cg-RX-API-DMAC10.html)
WO (1) WO2007079915A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200806946B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012533529A (ja) * 2009-07-17 2012-12-27 ポクセル・エスアーエス 虚血および/または再灌流関連疾患の処置に使用されるジヒドロ−1,3,5−トリアジンのアミノ誘導体

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3691650A1 (en) 2017-10-02 2020-08-12 Poxel Methods of treating heart failure with preserved ejection fraction
MY203360A (en) 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
EP4014962A1 (de) * 2020-12-16 2022-06-22 Novigo GmbH & Co. KG Zusammensetzung mit osmotisch wirksamer substanz und verwendung der zusammensetzung
FR3149774B1 (fr) * 2024-01-11 2025-06-20 Fabre Pierre Dermo Cosmetique 5,6,5’,6’-tétraphényl-3,3’-(1,4-phénylène)-bis[1,2,4]triazine pour améliorer l’aspect des cicatrices et/ou réduire les marques cicatricielles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520858A (ja) * 2000-01-26 2003-07-08 リファ ジヒドロ−1,3,5−トリアジンのアミン含有誘導体およびそれらの治療用用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150362A (en) * 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
CN1290264A (zh) * 1997-12-12 2001-04-04 艾博特公司 三嗪类血管生成抑制剂
US7622469B2 (en) * 2002-12-17 2009-11-24 Hamari Chemicals, Ltd. 2,4-diamino-1,3,5-triazine derivatives
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520858A (ja) * 2000-01-26 2003-07-08 リファ ジヒドロ−1,3,5−トリアジンのアミン含有誘導体およびそれらの治療用用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012533529A (ja) * 2009-07-17 2012-12-27 ポクセル・エスアーエス 虚血および/または再灌流関連疾患の処置に使用されるジヒドロ−1,3,5−トリアジンのアミノ誘導体

Also Published As

Publication number Publication date
KR101482686B1 (ko) 2015-01-14
PT1971329T (pt) 2017-11-24
SI1971329T1 (en) 2018-03-30
IL192595A (en) 2013-04-30
BRPI0620983A2 (pt) 2011-11-29
US8217040B2 (en) 2012-07-10
AU2006334732B2 (en) 2012-05-17
CA2636838A1 (en) 2007-07-19
EA016127B1 (ru) 2012-02-28
CY1119872T1 (el) 2018-06-27
BRPI0620983B8 (pt) 2021-05-25
LT1971329T (lt) 2018-01-25
CN101355931A (zh) 2009-01-28
FR2896161B1 (fr) 2008-04-04
EA200801678A1 (ru) 2008-12-30
WO2007079915A2 (en) 2007-07-19
HUE037217T2 (hu) 2018-08-28
DK1971329T3 (en) 2017-12-04
AR059034A1 (es) 2008-03-12
IL192595A0 (en) 2009-02-11
AU2006334732A1 (en) 2007-07-19
PL1971329T3 (pl) 2018-03-30
EP1971329A2 (en) 2008-09-24
EP1971329B1 (en) 2017-10-11
US20100168115A1 (en) 2010-07-01
KR20080088629A (ko) 2008-10-02
FR2896161A1 (fr) 2007-07-20
CA2636838C (en) 2015-05-05
WO2007079915A3 (en) 2007-08-30
ZA200806946B (en) 2009-11-25
ES2647912T3 (es) 2017-12-27
BRPI0620983B1 (pt) 2019-09-17

Similar Documents

Publication Publication Date Title
CN100420439C (zh) 双胍衍生物在制备具有瘢痕形成作用的医药产品中的应用
JP2902113B2 (ja) ケトロラク含有シップ剤
PT108978B (pt) Sais de tetraciclinas
TWI857116B (zh) 以抗真菌藥為有效成分之醫藥組合物
KR101482686B1 (ko) 상처치유 또는 혈관생성 효과를 갖는 약제의 제조를 위한트리아진 유도체의 용도
JP2015529196A (ja) ラサギリンの非経口製剤
CN111643494A (zh) 原花青素b2在制备具有抑制压力负荷型心室重构药物中的应用
JP2009500364A (ja) 創傷治癒を促進するための可溶性グアニル酸シクラーゼ活性化剤の使用
TW202339711A (zh) 預防或治療心血管疾病的高穿透性的阿司匹靈和其他非類固醇抗發炎藥的前藥
HK1128406A (en) Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect
JP5438239B1 (ja) シコニン誘導体を有するペリオスチンの発現抑制剤
JPH05271226A (ja) 創傷治癒促進剤
CN108774220B (zh) 用于治疗心肌缺血的化合物及其应用
US20200038348A1 (en) Methods and materials for reducing scar formation during wound healing
HK40112856A (en) Anti-fungal compositions
JP2024158843A (ja) リドカインゲル製剤
HK40024555B (en) External preparation for treating trichophytosis unguium
HK40024555A (en) External preparation for treating trichophytosis unguium
HK1223568B (en) Topical anti-inflammatory pharmaceutical composition with zileuton cream formulation

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120912

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121016